deltatrials
Completed PHASE2 NCT00455767

Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients

Phase IIA Multicenter 1 Week Treatment, Randomised, Double-Blind, Placebo Controlled Study of Depelestat in Patients Suffering From Acute Respiratory Distress Syndrome

Sponsor: Debiopharm International SA

Conditions Acute Respiratory Distress Syndrome Fibrosis Inflammation Lung Disease Pulmonary Fibrosis Respiratory Disorders Respiratory Distress Syndrome, Adult
Interventions EPI-hNE4 Placebo
Updated 6 times since 2017 Last updated: Jun 23, 2008 Started: Jul 31, 2006 Primary completion: Sep 30, 2007 Completion: Sep 30, 2007

A PHASE2 clinical study on Acute Respiratory Distress Syndrome and Fibrosis, this trial is completed. The trial is conducted by Debiopharm International SA and has accumulated 6 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Jul 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Debiopharm International SA
Data source: Debiopharm International SA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Angers, France, Barcelona, Spain, Bordeaux, France, Créteil, France, Grenoble, France, Lyon, France, Monastir, Tunisia, Montpellier, France, Paris, France, Roma, Italy and 2 more location s